Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 4/2012

Open Access 01-12-2012 | Original Paper

Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4

Authors: Zhao-Hui Jin, Takako Furukawa, Michael Claron, Didier Boturyn, Jean-Luc Coll, Toshimitsu Fukumura, Yasuhisa Fujibayashi, Pascal Dumy, Tsuneo Saga

Published in: Angiogenesis | Issue 4/2012

Login to get access

Abstract

64Cu-cyclam-RAFT-c(-RGDfK-)4 is a novel multimeric positron emission tomography (PET) probe for αVβ3 integrin imaging. Its uptake and αVβ3 expression in tumors showed a linear correlation. Since αVβ3 integrin is strongly expressed on activated endothelial cells during angiogenesis, we aimed to determine whether 64Cu-cyclam-RAFT-c(-RGDfK-)4 PET can be used to image tumor angiogenesis and monitor the antiangiogenic effect of a novel multi-targeted tyrosine kinase inhibitor, TSU-68. Athymic nude mice bearing human hepatocellular carcinoma HuH-7 xenografts, which expressed negligible αVβ3 levels on the tumor cells, received intraperitoneal injections of TSU-68 or the vehicle for 14 days. Antiangiogenic effects were determined at the end of therapy in terms of 64Cu-cyclam-RAFT-c(-RGDfK-)4 uptake evaluated using PET, biodistribution assay, and autoradiography, and they were compared with microvessel density (MVD) determined by CD31 immunostaining. 64Cu-cyclam-RAFT-c(-RGDfK-)4 PET enabled clear tumor visualization by targeting the vasculature, and the biodistribution assay indicated high tumor-to-blood and tumor-to-muscle ratios of 31.6 ± 6.3 and 6.7 ± 1.1, respectively, 3 h after probe injection. TSU-68 significantly slowed tumor growth and reduced MVD; these findings were consistent with a significant reduction in the tumor 64Cu-cyclam-RAFT-c(-RGDfK-)4 uptake. Moreover, a linear correlation was observed between tumor MVD and the corresponding standardized uptake value (SUV) (r = 0.829, P = 0.011 for SUVmean; r = 0.776, P = 0.024 for SUVmax) determined by quantitative PET. Autoradiography and immunostaining showed that the distribution of intratumoral radioactivity and tumor vasculature corresponded. We concluded that 64Cu-cyclam-RAFT-c(-RGDfK-)4 PET can be used for in vivo angiogenesis imaging and monitoring of tumor response to antiangiogenic therapy.
Appendix
Available only for authorised users
Literature
1.
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(Suppl 16):15–18PubMed
2.
Prager GW, Poettler M (2011) Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie 32:105–114
3.
Augustin HG (2003) Translating angiogenesis research into the clinic: the challenges ahead. Br J Radiol 76:S3–10PubMedCrossRef
4.
Rosen L (2000) Antiangiogenic strategies and agents in clinical trials. Oncologist 5(Suppl 1):20–27PubMedCrossRef
5.
Wu HC, Huang CT, Chang DK (2008) Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol 4:37–45
6.
Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T (2011) Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 18:3136–3155PubMedCrossRef
7.
8.
Rudin M, Weissleder R (2003) Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2:123–131PubMedCrossRef
9.
Almuhaideb A, Papathanasiou N, Bomanji J (2011) 18F-FDG PET/CT imaging in oncology. Ann Saudi Med 31:3–13PubMedCrossRef
10.
Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, Shen B, Niu G, Chen X (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52:140–146PubMedCrossRef
11.
Yang M, Gao H, Yan Y, Sun X, Chen K, Quan Q, Lang L, Kiesewetter D, Niu G, Chen X (2011) PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 38:1237–1247PubMedCrossRef
12.
Stromblad S, Cheresh DA (1996) Integrins, angiogenesis and vascular cell survival. Chem Biol 3:881–885PubMedCrossRef
13.
Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H (1996) Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αVβ3 antagonists. J Am Chem Soc 118:7461–7472CrossRef
14.
Haubner R (2006) αVβ3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 33(Suppl 1):54–63PubMedCrossRef
15.
Dijkgraaf I, Beer AJ, Wester HJ (2009) Application of RGD-containing peptides as imaging probes for αVβ3 expression. Front Biosci 14:887–899PubMedCrossRef
16.
Choyke PL (2011) Pilot study of FPPRGD2 for imaging αVβ3 integrin–how integral are integrins? Radiology 260:1–2PubMedCrossRef
17.
Beer AJ, Kessler H, Wester HJ, Schwaiger M (2011) PET imaging of integrin αVβ3 expression. Theranostics 1:48–57PubMedCrossRef
18.
Jung KH, Lee KH, Paik JY, Ko BH, Bae JS, Lee BC, Sung HJ, Kim DH, Choe YS, Chi DY (2006) Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med 47:2000–2007PubMed
19.
Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA (2009) Noninvasive imaging of αVβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res 69:3173–3179PubMedCrossRef
20.
Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR (2009) Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 50:116–122PubMedCrossRef
21.
Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVβ3-integrin and αVβ5-integrin imaging agent. J Nucl Med 52:424–430PubMedCrossRef
22.
Boturyn D, Coll JL, Garanger E, Favrot MC, Dumy P (2004) Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc 126:5730–5739PubMedCrossRef
23.
Galibert M, Jin ZH, Furukawa T, Fukumura T, Saga T, Fujibayashi Y, Dumy P, Boturyn D (2010) RGD-cyclam conjugate: synthesis and potential application for positron emission tomography. Bioorg Med Chem Lett 20:5422–5425PubMedCrossRef
24.
Jin ZH, Furukawa T, Galibert M, Boturyn D, Coll JL, Fukumura T, Saga T, Dumy P, Fujibayashi Y (2011) Noninvasive visualization and quantification of tumor αVβ3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4. Nucl Med Biol 38:529–540PubMedCrossRef
25.
Jin ZH, Josserand V, Foillard S, Boturyn D, Dumy P, Favrot MC, Coll JL (2007) In vivo optical imaging of integrin αVβ3 in mice using multivalent or monovalent cRGD targeting vectors. Mol Cancer 6:41–50PubMedCrossRef
26.
Yoshitomi H, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Miyazaki M (2008) Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 37:275–281PubMedCrossRef
27.
Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22PubMedCrossRef
28.
Sancey L, Ardisson V, Riou LM, Ahmadi M, Marti-Batlle D, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP (2007) In vivo imaging of tumour angiogenesis in mice with the αVβ3 integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging 34:2037–2047PubMedCrossRef
29.
Ahmadi M, Sancey L, Briat A, Riou L, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP (2008) Chemical and biological evaluations of an 111In-labeled RGD-peptide targeting integrin Alpha(V) Beta(3) in a preclinical tumor model. Cancer Biother Radiopharm 23:691–700PubMedCrossRef
30.
Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges-Rizo C, Boturyn D, Souchier C, Grichine A, Dumy P, Coll JL (2009) Clustering and internalization of integrin αVβ3 with a tetrameric RGD-synthetic peptide. Mol Ther 17:837–843PubMedCrossRef
31.
Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M (2005) Noninvasive visualization of the activated αVβ3 integrin in cancer patients by positron emission tomography and p18F]galacto-RGD. PLoS Med 2:e70PubMedCrossRef
32.
Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ, Chin FT, Chen X (2010) 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αVβ3 integrin expression. Mol Imaging Biol 12:530–538PubMedCrossRef
33.
Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152–4160PubMed
34.
Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Arioka H, Tamura T (2011) Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:1101–1109PubMedCrossRef
35.
Murakami H, Ueda Y, Shimoyama T, Yamamoto N, Yamada Y, Arioka H, Tamura T (2011) Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol 67:1119–1128PubMedCrossRef
36.
Melis M, Bijster M, de Visser M, Konijnenberg MW, de Swart J, Rolleman EJ, Boerman OC, Krenning EP, de Jong M (2009) Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 36:1968–1976PubMedCrossRef
37.
Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, Gotthardt M, Boerman OC (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049–1058PubMedCrossRef
38.
Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO (2008) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49:879–886PubMedCrossRef
39.
Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS (2011) Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αVβ3 integrin levels. Radiology 260:182–191PubMedCrossRef
40.
Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, Shen B, Niu G, Chen X (2011) Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 22:2415–2422PubMedCrossRef
Metadata
Title
Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4
Authors
Zhao-Hui Jin
Takako Furukawa
Michael Claron
Didier Boturyn
Jean-Luc Coll
Toshimitsu Fukumura
Yasuhisa Fujibayashi
Pascal Dumy
Tsuneo Saga
Publication date
01-12-2012
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 4/2012
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-012-9281-1

Other articles of this Issue 4/2012

Angiogenesis 4/2012 Go to the issue

Original Paper

Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies

Original Paper

Contrasting effects of sunitinib within in vivo models of metastasis

Original Paper

RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans

Review Paper

Emerging biotechnological strategies for non-viral antiangiogenic gene therapy

Original Paper

miR-20a represses endothelial cell migration by targeting MKK3 and inhibiting p38 MAP kinase activation in response to VEGF

Original Paper

An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits